Grand Opening | 2023 China Focus@Boston is open for registration

In the past 2022, according to incomplete statistics, there were a total of 130 license in/out transactions between biopharmaceuticals in China and around the world, including 80 license in transactions and 51 license out transactions. Innovative pharmaceutical companies in China are accelerating their research and development, and China’s License out has become an important means for enterprises to move towards globalization. Chinese pharmaceutical companies must always maintain a keen sense of global biopharmaceutical market trends and seize opportunities while dedicating themselves to accelerating clinical product development.

At 2023 China Focus @Boston, we will invite MNC Global BD Head, Chairman/CEO of Chinese listed companies, CEOs and BD executives of Chinese and foreign Biotech companies, partners of investment institutions and other industry insiders to discuss topics such as the internationalization strategy of Chinese enterprises, MNC’s strategic layout in the world, China Biotech’s investment and financing strategies, and global investment and opportunities in synthetic biology.

The conference will be focused on two main topics: biopharmaceutical investment BD cooperation and process technology exploration, and a special roadshow for Chinese biopharmaceutical enterprises.

Registration: Scan the QR code to register. Once approved, an email notification will be sent.

↓ Consulting

Click 'Read More' to reach the conference website.